Status:

TERMINATED

N-Terminal Pro-brain Natriuretic Peptide Hormone and Persistent Pulmonary Hypertension

Lead Sponsor:

Christiana Care Health Services

Collaborating Sponsors:

Thomas Jefferson University

Conditions:

Persistent Pulmonary Hypertension of Newborn

Eligibility:

All Genders

Up to 6 years

Brief Summary

Babies who are suspected of having persistent pulmonary hypertension (PPHN) will be included in this study. PPHN is a condition in which the blood is restricted from flowing to the lungs in a normal w...

Detailed Description

PPHN occurs in infant \> or = 34 weeks gestation and is characterized by an elevation in pulmonary vascular resistance (PVR) and right-to-left shunting of the blood at the atrial, ductal, and pulmonar...

Eligibility Criteria

Inclusion

  • \>/= 34 weeks gestation at birth
  • clinical diagnosis of PPHN

Exclusion

  • newborns with evidence of structural heart disease, congenital anomalies and prior use of inhaled nitric oxide.

Key Trial Info

Start Date :

February 1 2007

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 1 2008

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT00443859

Start Date

February 1 2007

End Date

September 1 2008

Last Update

July 11 2016

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Christiana Hospital

Newark, Delaware, United States, 19718

2

Thomas Jefferson University

Philadelphia, Pennsylvania, United States, 19107

N-Terminal Pro-brain Natriuretic Peptide Hormone and Persistent Pulmonary Hypertension | DecenTrialz